Please try another search
Lirum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the treatment of debilitating diseases. Its lead product candidate is LX-101, an insulin-like growth factor-1 receptor directed agent to treat patients with various cancers and autoimmune diseases, including thyroid eye disease. The company was incorporated in 2021 and is based in New York, New York.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review